BRIM BIOTECHNOLOGY, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.45 TWD | -2.84% |
|
+7.99% | +8.35% |
| 2023 | BRIM Biotechnology, Inc.(TPEX:6885) added to S&P Global BMI Index | CI |
| 2022 | BRIM Biotechnology, Inc. announced that it has received $20 million in funding | CI |
| Sales 2022 | 0.53 17.14 0.72 | Sales 2023 | 0.09 2.93 0.12 | Capitalization | 3.47B 113B 4.74B |
|---|---|---|---|---|---|
| Net income 2022 | -274M -8.93B -375M | Net income 2023 | -688M -22.41B -940M | EV / Sales 2022 | 5,182,680,798 x |
| Net cash position 2022 | 832M 27.09B 1.14B | Net cash position 2023 | 1.69B 55.12B 2.31B | EV / Sales 2023 | 19,719,958,889 x |
| P/E ratio 2022 |
-9.92
x | P/E ratio 2023 |
-4.38
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
| 1 day | -2.84% | ||
| 1 week | +7.99% | ||
| Current month | -1.07% | ||
| 1 month | -4.42% | ||
| 3 months | +13.26% | ||
| 6 months | -54.93% | ||
| Current year | +8.35% |
1 week
29.35
33.85
1 month
29.3034.70
Current year
26.6539.35
1 year
24.6087.80
3 years
24.0092.00
5 years
24.0092.00
10 years
24.0092.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hai Shan Jian
CEO | Chief Executive Officer | - | 13-07-30 |
Wen Chi Lee
FOU | Founder | - | 13-07-30 |
Fu Pin Wu
DFI | Director of Finance/CFO | - | 22-04-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ta Kun Shih
BRD | Director/Board Member | 72 | 22-03-14 |
Hsiu Lien Lin
BRD | Director/Board Member | - | 22-03-14 |
Hai Shan Jian
CEO | Chief Executive Officer | - | 13-07-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 32.45 | -2.84% | 625,477 |
| 24-04-25 | 33.4 | +5.20% | 1,991,485 |
| 24-04-24 | 31.75 | +5.83% | 1,102,405 |
| 24-04-23 | 30 | +1.01% | 138,072 |
| 24-04-22 | 29.7 | -1.16% | 437,823 |
End-of-day quote Taipei Exchange, April 25, 2024
More quotes
BRIM Biotechnology Inc is a Taiwan-based company mainly engaged in drug discovery and development. The Company's product line is based on the pigment epithelium-derived factor (PEDF) and its derived short-chain polypeptide technology platform for multiple therapeutic areas and indications. The Company has four product candidates, BRM421 Dry Eye, BRM423 Severe Corneal Injury, BRM424 Neurotrophic Keratitis and BRM521 Degenerative Arthritis. BRM421 is primarily indicated for the treatment and repair of dry eye disease (DES) with corneal damage.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +8.35% | 115M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 6885 Stock
